featured
First-Line Zolbetuximab Plus mFOLFOX6 for CLDN18.2+, HER2−, Locally Advanced, Unresectable or Metastatic Gastric or GEJ Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Lancet 2023 May 20;401(10389)1655-1668, K Shitara, F Lordick, YJ Bang, P Enzinger, D Ilson, MA Shah, E Van Cutsem, RH Xu, G Aprile, J Xu, J Chao, R Pazo-Cid, YK Kang, J Yang, D Moran, P Bhattacharya, A Arozullah, JW Park, M Oh, JA AjaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.